&w=3840&q=100)
India Cements declines 5% as company incurs net loss against profit YoY
At 10:33 AM, India Cements share price was trading 2.62 per cent lower at ₹338.1 per share on the BSE. In comparison, the BSE Sensex was up 0.41 per cent at 82,089.66.
The company's market capitalisation stood at ₹10,477.62 crore. The 52-week high of the stock was at ₹385.5 per share, and the 52-week low of the stock was at ₹239 per share.
India Cements Q1 results
India Cements, a subsidiary of UltraTech Cement, reported a consolidated net loss of ₹132.9 crore for the April-June 2025 quarter, as compared to a net profit of ₹58.47 crore a year ago.
The consolidated total income for the quarter under review was ₹1,033.85 crore, compared to ₹1,042.27 crore a year ago.
Its Earnings before interest, tax, depreciation and amortisation (Ebitda) stood at ₹92 crore in quarter under review, as against Ebitda loss of ₹9 crore a year ago. Net sales for the quarter stood at ₹1,025 crore as compared to ₹1,027 crore a year ago.
During the quarter, the company approved the sale of its entire equity stake in its subsidiary, Industrial Chemicals and Monomers Ltd.
It also said it had successfully refinanced its debt, resulting in a significant reduction in finance costs, from ₹82.36 crore in the corresponding quarter last year to ₹26.58 crore.
"The company is planning a capital expenditure programme over the next two years to improve efficiency and reduce operating costs; increase the share of renewable power; and enhance safety standards," India Cements said.
Profitability is expected to improve further as the benefits of this capex programme begin to flow in, along with synergies from economies of scale, a wider distribution network, and a stronger balance sheet.
About India Cements
India Cements Limited is a subsidiary of UltraTech Cement Limited. UltraTech is the cement flagship company of the Aditya Birla Group and is the largest manufacturer of grey cement and ready mix concrete (RMC) and one of the largest manufacturers of white cement in India. India Cements was acquired by UltraTech on December 24, 2024.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
6 minutes ago
- Business Standard
This MFI lender's stock soars 7% even as Q1 profit plunges; Here's why
Shares of CreditAccess Grameen rose over 7 per cent on Wednesday even after the company reported an 85 per cent year-on-year (Y-o-Y) to ₹60.2 crore for the quarter ended June 2025 (Q1FY26). The micro finance lender's stock rose as much as 7.05 per cent during the day to ₹1,370 per share. The stock pared gains to trade 5.3 per cent higher at ₹1,347 apiece, compared to a 0.43 per cent advance in Nifty 50 as of 1:10 PM. Shares of the company have been range-bound since July, and at day's high, the stock was at the highest level since July 2, 2024. The counter has risen 52 per cent this year, compared to a 6.2 per cent advance in the benchmark Nifty 50. CreditAccess Grameen has a total market capitalisation of ₹21,496.25 crore, according to BSE data. CreditAccess Grameen Q1 results The microfinance lender's net profit declined 85 per cent Y-o-Y primarily to ₹60.2 crore contraction in net interest income and higher provisioning. Sequentially, the net profit rose 27.5 per cent from Rs 47.2 crore in the quarter ended March 2025 (Q4FY25). The lender's net interest income (NII) declined 1.6 per cent to ₹937 crore. Sequentially, NII grew 7 per cent from ₹876.1 crore in Q4FY25. Its net interest margin (NIM) dropped to 12.8 per cent in Q1FY26 from 13.0 per cent in Q1FY25. However, it improved from 12.7 per cent in Q4FY25. The company's gross non-performing assets (NPAs) rose sharply to 4.70 per cent as of June 2025, up from 1.46 per cent a year ago. It, however, declined from 4.76 per cent at the end of March 2025. Analysts bullish on CreditAccess Grameen While the microfinance industry (MFI) is still navigating stress, JM Financial believes CreditAccess Grameen is best positioned to recover early. This is due to its strong stress recognition framework, along with an accelerated write-off policy and high expected credit loss coverage. Management expects elevated credit costs to persist in Q2FY25, before moderating to 3-3.5 per cent in the second half of FY25. FY26 guidance for loan growth and return on equity (RoE) has been maintained at 14-18 per cent and 11.8-13.3 per cent, respectively, with stronger momentum expected in the second half, particularly from the retail finance book. JM Financial expects around 15 per cent assets under management CAGR over FY25-27. Given the improving outlook, the brokerage has upgraded the stock to 'Buy' and revised the target price to ₹1,475. Analysts at Motilal Oswal said that the lender has successfully navigated a period of industry-wide challenges, demonstrating remarkable resilience and a return to normal operational efficiency. The company will continue to prioritise balance sheet normalisation through accelerated write-offs and prudent provisioning, it said.
&w=3840&q=100)
Business Standard
6 minutes ago
- Business Standard
Concord Biotech rises 2% on incorporating its arm for marketing and sales
Concord Biotech shares rose 2.3 per cent, logging an intraday high at ₹1941.25 per share on the BSE. At 1:22 PM, Concord Biotech share price was trading 1.72 per cent higher at ₹1,930 per share on BSE. In comparison, the BSE Sensex rose 0.43 per cent to 82,544.23. The market capitalisation of the company stood at ₹20,190.93 crore. The 52-week high of the company stood at ₹2,658 per share, and the 52-week low was at ₹1,370.05. Why were Concord Biotech shares buzzing in trade? The buying on the counter came after the company incorporated its subsidiary Concord Lifegen, with an objective to carry out marketing, sales, and distribution of pharmaceutical products. The total cost of acquisition is worth ₹1,00,000. "We are pleased to announce incorporation of Concord's Wholly Owned subsidiary company, namely, 'Concord Lifegen Limited' with objective to carry out marketing, sales, and distribution of pharmaceutical products," the filing read. Its primary objectives include executing targeted sales strategies, ensuring regulatory compliance across domestic and international markets, handling logistics and customer support, and maintaining transparent reporting to the holding company, according to the filing. The authorised share capital (as on July 22, 2025) of Concord Lifegen is ₹1,00,000 divided into 10,000 equity shares of ₹10 each issued share capital (as on July 22, 2025). That apart, in Q4, the company's profit climbed 47.8 per cent year-on-year (Y-o-Y) to ₹140 crore in the March quarter of FY25, from ₹95 crore in the March quarter of FY24. Concord Biotech's revenue from operations surged 34.8 per cent Y-o-Y to ₹429.9 crore in Q4FY25, from ₹319 crore in the same quarter a year ago. About Concord Biotech Concord Biotech is a research-driven biopharmaceutical company specialising in the production of Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations. Initially a single-product entity, Concord has evolved into a comprehensive solutions provider, offering a broad range of products across various therapeutic segments. The company has established a global presence, distributing its products in over 70 countries, including key markets like the USA, Europe, Japan, and Latin America, while also maintaining a major footprint in India.
&w=3840&q=100)
Business Standard
6 minutes ago
- Business Standard
Monarch Surveyors IPO booked 37x; GMP up 68%; check who is driving demand
Monarch Surveyors IPO comprises an entirely fresh issue of 3.75 million equity shares estimated to be worth ₹93.75 crore. The public offering is available at a price band of ₹237-250 per share. SI Reporter New Delhi Monarch Surveyors IPO Day 2 subscription status: Retail investors were leading the demand for the initial public offering of Monarch Surveyors & Engineering Consultants (Monarch Surveyors IPO) on the second day of its subscription period. The demand for the public issue was also strong among the institutional investors, as the public issue has been oversubscribed by 37.20 times till around 1:20 PM on Wednesday, July 23, 2025. The BSE data shows that the retail investors have placed the highest bids by oversubscribing the category reserved for them by 58.75 times, followed by non-institutional investors (NIIs) at 34.46 times and qualified institutional buyers (QIBs) at 2.27 times. Monarch Surveyors IPO details Monarch Surveyors IPO comprises an entirely fresh issue of 3.75 million equity shares estimated to be worth ₹93.75 crore. The public offering is available at a price band of ₹237–250 per share, and a lot size of 600 shares. The investors can bid for a minimum of 1,200 shares and in multiples of 600 shares thereafter, and would require a minimum of ₹3,00,000 to bid for 2 lots or 1,200 shares of Monarch Surveyors IPO. The company intends to use the net proceeds from the public issue for funding the capital expenditure requirement for purchase of machinery, as well as for funding working capital requirements of the company. The company will further use the proceeds for general corporate purposes. Monarch Surveyors IPO grey market premium (GMP) The unlisted shares of the company continued to trade at a solid premium in the grey markets on Wednesday. Monarch Surveyors shares were trading at around ₹420 per share, reflecting a grey market premium (GMP) of ₹170 or 68 per cent over the upper end of the issue price, according to sources tracking unofficial market activities. Monarch Surveyors IPO allotment date, listing date The three-day subscription window to bid for the Monarch Surveyors IPO is set to conclude on July 24, 2025. Following the closure of the subscription window, the basis of allotment of Monarch Surveyors is set to take place on July 25. The company's shares will be credited into demat accounts tentatively by July 28. About Monarch Surveyors Founded in 1999, Monarch Surveyors & Engineering Consultants offer end-to-end infrastructure consultancy services. The company operates in sectors such as transportation, urban planning, environment, and water. Monarch offers services including high-precision engineering surveys, feasibility studies, and project management. The company has worked with Indian government institutions, road authorities, and private entities. Monarch also has a presence in Sri Lanka and Bhutan, delivering data-driven engineering solutions. The company's services span the entire lifecycle of infrastructure projects, from concept to commissioning. Monarch's expertise includes surveying, design services, and technical supervision for various civil engineering sectors.
